The presence of RET/TPC1 rearrangement in a significant proportion (38.2%) of the patients with BRAF and RAS wild-type PTCs can be used to diagnose and manage patients with BRAF and RAS wild-type indeterminate thyroid nodules. The gene discussed is BRAF; the disease is thyroid nodule.